GSK stock trades for 13 times earnings and barely 11 times free cash flow. The pharmaceutical giant pays a 3.3% dividend ...

IDEAYA Biosciences ( ($IDYA) ) has shared an update. On December 4, 2025, GlaxoSmithKline announced its decision to terminate its collaboration ...

GSK’s fair value estimate has increased from £18.07 to £18.27, indicating a minor but notable shift in analysts’ outlook for ...

GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GSK plc announced the grant of options over Ordinary Shares as part of its Share Save ...

GSK (LSE:GSK) has quietly kept shareholders happy this year, with the stock climbing about 34% year to date and roughly 42% ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock ...

GSK's 2024 results are strong, with a promising shift toward specialty medicines, particularly in HIV, respiratory conditions, and cancer, driving long-term growth. Key drugs Blenrep and Depemokimab ...

GSK plc (NYSE:GSK) on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Under the agreement, GSK will pay up to $2 billion in total cash consideration. This includes ...

GSK's Tesaro sues AnaptysBio over alleged Jemperli contract breaches, putting royalties, milestones, and future licensing ...